Viewing nowDirtan Tablet 80mg (Valsartan)
Valsartan 80mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

MFDS item code 201802079 · Approved 2018.05.16 · Insurance code 647205140
Treatment of essential hypertension; reduction of the risk of death after myocardial infarction; treatment of heart failure
This drug is used for the treatment of essential hypertension and heart failure patients without ACE inhibitor intolerance (NYHA class II to IV). It also helps to reduce the risk of death in stable patients showing symptoms or left ventricular dysfunction after myocardial infarction. Therefore, this medication is effectively used for blood pressure control, improvement of heart failure symptoms, and improvement of prognosis after myocardial infarction.
1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take the medicine at the same time each day (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be co-administered. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dosage adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: For patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: For patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When a diuretic is co-administered, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily. Over the following several weeks, the dose may be increased, taking the patient's tolerability into account, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, co-administration with an ACE inhibitor is not recommended. 4. Patients with renal impairment : No dosage adjustment is necessary for patients with creatinine clearance of 10 mL/min or higher. However, this medicine should not be administered to patients with creatinine clearance less than 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment : For patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If doses of 80 mg or more per day are used, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age. The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.
This drug can cause serious damage to the fetus if taken during pregnancy, especially during the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. This drug should not be used in patients with certain diseases, such as severe liver impairment, severe kidney impairment, a history of angioedema, pregnant women, or nursing mothers. Elderly patients or those with hyperkalemia, mild to moderate liver impairment, or cardiovascular disease should be particularly careful when using this drug, and the risk of hypotension or worsening kidney function should always be monitored. Side effects such as headache, dizziness, fatigue, cough, and diarrhea may occur during treatment with this drug; consult a healthcare professional if symptoms are severe or persistent. In patients with heart failure or after myocardial infarction, kidney function and electrolyte status should be monitored regularly and appropriate action should be taken if abnormalities are found. This drug can interact with other medications, so caution is needed when used in combination with potassium-sparing diuretics, potassium supplements, or non-steroidal anti-inflammatory drugs (NSAIDs). Women who are pregnant or planning to become pregnant should not take this drug, and nursing mothers are advised to avoid use as well. The safety and efficacy of this drug have not been established in children and adolescents under 18 years of age, thus it is not recommended. In case of overdose, severe hypotension, decreased consciousness, or shock may occur, so seek immediate medical attention for appropriate treatment. This drug should be kept out of reach of children, and it is important to avoid transferring it to other containers.
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a sealed container to prevent air and moisture intrusion. Additionally, it is important to store it in a cool place below 30 degrees Celsius to maintain the drug's effectiveness.
Pink round film-coated tablets
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 80mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.